Aug 7, 2026 07:34AM
Aug 7, 2026 07:00AM
Jul 2, 2026 07:00AM
Jun 18, 2026 07:03AM
Jun 18, 2026 07:00AM
May 18, 2026 04:46PM
May 8, 2026 08:19AM Kiora Pharmaceuticals (KPRX) Misses Q1 EPS by 58c
May 8, 2026 07:00AM
Apr 14, 2026 07:02AM
Apr 14, 2026 07:00AM
Apr 7, 2026 07:01AM
Apr 7, 2026 07:00AM
Apr 2, 2026 04:31PM
Apr 2, 2026 04:30PM Kiora Pharmaceuticals Announces Management Team Changes
Mar 25, 2026 07:02AM
Mar 25, 2026 07:00AM
Feb 19, 2026 08:30AM
Jan 27, 2026 07:03AM
Jan 27, 2026 07:00AM
Dec 1, 2025 06:47AM
Dec 1, 2025 06:45AM Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Nov 7, 2025 06:49AM
Nov 7, 2025 06:02AM
Nov 7, 2025 06:00AM
Oct 30, 2025 09:01AM
Oct 15, 2025 07:00AM
Sep 4, 2025 07:00AM
Aug 8, 2025 07:02AM Kiora Pharmaceuticals reports Q2 2025 results with two phase 2 trials
Aug 8, 2025 07:00AM
Aug 7, 2025 07:00AM
Jul 22, 2025 08:57AM
Jul 22, 2025 08:55AM
Jun 3, 2025 07:02AM
Jun 3, 2025 07:00AM
May 9, 2025 07:35AM Kiora Pharmaceuticals (KPRX) Misses Q1 EPS by 52c
May 9, 2025 07:00AM
May 5, 2025 07:00AM
Apr 4, 2025 07:00AM
Mar 25, 2025 07:00AM
Mar 12, 2025 07:00AM
Feb 13, 2025 07:03AM
Feb 13, 2025 07:00AM Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Feb 11, 2025 06:46AM
Feb 11, 2025 06:45AM
Nov 12, 2024 07:50AM
Nov 8, 2024 07:36AM
Nov 8, 2024 07:00AM
Oct 29, 2024 06:47AM
Oct 29, 2024 06:45AM Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Sep 25, 2024 09:55AM

434,435 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All